The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study
These findings suggest that the administration sequence of chemotherapy followed by ICIs may yield the greatest clinical benefit, providing a basis for clinical decision-making.
Authors
- Bicheng Zhang (ORCID: https://orcid.org/0000-0002-6759-6748)
- Min Qian (ORCID: https://orcid.org/0000-0003-1214-8830)
- Jun Wang (ORCID: https://orcid.org/0000-0003-3941-2507)
- Jiaxin Yin
- Yang Fu (ORCID: https://orcid.org/0000-0003-1023-2449)
- Yuxiao Song
- Weiting Cheng (ORCID: https://orcid.org/0000-0003-1526-4335)
Institutions
- Hubei University of Chinese Medicine (CN)
- Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
- Shandong First Medical University (CN)
- Xiangyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fimmu.2025.1579420
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology